Related Experiment Video
Updated: Dec 29, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Anlotinib in treatment of an elderly patient with recurrent advanced SCLC
Ying Zhang1, Beili Jia1, Jing Li1
1Department of Internal Medicine, Municipal Hospital, Qingdao, Shandong, People's Republic of China.
Introduction:
An elderly patient with advanced small cell lung cancer who had a history of smoking and who had previously had tuberculosis and chronic kidney disease relapsed after classical treatment with etoposide combined with carboplatin.
Methods:
The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment. The last medication was apatinib.
Results:
After treatment with anlotinib, the patient has survived for 15 months with good quality of life.
Conclusion:
This is the first report on the precise efficacy of anlotinib in the treatment of advanced small cell lung cancer. Anlotinib is an important option for patients with small cell lung cancer.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Treatment Resistant Cancers
Drug Dosing: Geriatric Patients